Zhou, C., Huang, D., Yu, X., Liu, Y., Fan, Y., Shu, Y., Ma, Z., Wang, Z., Cheng, Y., Wang, J., Hu, S., Liu, Z., Poddubskaya, E., Disel, U., Akopov, A., Ma, Y., Wang, Y., Li, S., Yu, C., Barnes, G., Tang, B., & Rivalland, G. (n.d.). efficacy, safety, and health-related quality of life from a global phase 3 study of tislelizumab as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): RATIONALE 303. Lung cancer, 165, S32–S33. http://access.bl.uk/ark:/81055/vdc_100150604955.0x000050